APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Targeted Drugs for Neurodegenerative Diseases

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Targeted Drugs for Neurodegenerative Diseases Industry Growth and Trends Forecast to 2032

Report ID 174039780127 December 2025112 pages

Choose your research edition.

Industry ResearchTargeted Drugs for Neurodegenerative Diseases Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Targeted Drugs for Neurodegenerative Diseases Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Targeted Drugs for Neurodegenerative Diseases Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Targeted Drugs for Neurodegenerative Diseases Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Targeted Drugs for Neurodegenerative Diseases Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

According to APO Research, the global Targeted Drugs for Neurodegenerative Diseases market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Targeted Drugs for Neurodegenerative Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Targeted Drugs for Neurodegenerative Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Targeted Drugs for Neurodegenerative Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Targeted Drugs for Neurodegenerative Diseases market include Eisai Inc., Teva, NOVARTIS, Green Valley, Roche, Lundbeck, Eli Lilly, Biogen and UCB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Targeted Drugs for Neurodegenerative Diseases market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Targeted Drugs for Neurodegenerative Diseases market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Targeted Drugs for Neurodegenerative Diseases market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Targeted Drugs for Neurodegenerative Diseases.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Targeted Drugs for Neurodegenerative Diseases market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Targeted Drugs for Neurodegenerative Diseases Market by Company

Eisai Inc.

Teva

NOVARTIS

Green Valley

Roche

Lundbeck

Eli Lilly

Biogen

UCB

Supernus Pharmaceuticals

Sumitomo Pharma

Sanofi

Neurocrine

Kyowa Kirin

Janssen

Bristol-Myers Squibb

Acadia Pharmaceuticals Inc.

Targeted Drugs for Neurodegenerative Diseases Segment by Type

Oral

Injection

Targeted Drugs for Neurodegenerative Diseases Segment by Application

Parkinson's Disease (PD)

Huntington's Disease (HD)

Multiple Sclerosis (MS)

Tardive Dyskinesia (TD)

Alzheimer's Disease (AD)

Targeted Drugs for Neurodegenerative Diseases Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted Drugs for Neurodegenerative Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Targeted Drugs for Neurodegenerative Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted Drugs for Neurodegenerative Diseases.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Targeted Drugs for Neurodegenerative Diseases companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Targeted Drugs for Neurodegenerative Diseases Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region (2021-2026) Table 4. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region (2027-2032) Table 6. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Targeted Drugs for Neurodegenerative Diseases Market Size Share by Type (2021-2026) Table 9. Global Targeted Drugs for Neurodegenerative Diseases Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Targeted Drugs for Neurodegenerative Diseases Market Size Share Forecasted by Type (2027-2032) Table 11. North America Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Targeted Drugs for Neurodegenerative Diseases Market Size Share by Application (2021-2026) Table 24. Global Targeted Drugs for Neurodegenerative Diseases Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Targeted Drugs for Neurodegenerative Diseases Market Size Share Forecasted by Application (2027-2032) Table 26. North America Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Targeted Drugs for Neurodegenerative Diseases Industry Trends Table 37. Targeted Drugs for Neurodegenerative Diseases Industry Drivers Table 38. Targeted Drugs for Neurodegenerative Diseases Industry Opportunities and Challenges Table 39. Targeted Drugs for Neurodegenerative Diseases Industry Restraints Table 40. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Company (2021-2026) Table 42. Global Targeted Drugs for Neurodegenerative Diseases Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Targeted Drugs for Neurodegenerative Diseases Key Company Headquarters & Area Served Table 44. Global Targeted Drugs for Neurodegenerative Diseases Company, Product Type & Application Table 45. Global Targeted Drugs for Neurodegenerative Diseases Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Targeted Drugs for Neurodegenerative Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Eisai Inc. Company Information Table 49. Eisai Inc. Business Overview Table 50. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 52. Eisai Inc. Recent Development Table 53. Teva Company Information Table 54. Teva Business Overview Table 55. Teva Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Teva Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 57. Teva Recent Development Table 58. NOVARTIS Company Information Table 59. NOVARTIS Business Overview Table 60. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 62. NOVARTIS Recent Development Table 63. Green Valley Company Information Table 64. Green Valley Business Overview Table 65. Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Green Valley Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 67. Green Valley Recent Development Table 68. Roche Company Information Table 69. Roche Business Overview Table 70. Roche Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Roche Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 72. Roche Recent Development Table 73. Lundbeck Company Information Table 74. Lundbeck Business Overview Table 75. Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 77. Lundbeck Recent Development Table 78. Eli Lilly Company Information Table 79. Eli Lilly Business Overview Table 80. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 82. Eli Lilly Recent Development Table 83. Biogen Company Information Table 84. Biogen Business Overview Table 85. Biogen Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Biogen Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 87. Biogen Recent Development Table 88. UCB Company Information Table 89. UCB Business Overview Table 90. UCB Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. UCB Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 92. UCB Recent Development Table 93. Supernus Pharmaceuticals Company Information Table 94. Supernus Pharmaceuticals Business Overview Table 95. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 97. Supernus Pharmaceuticals Recent Development Table 98. Sumitomo Pharma Company Information Table 99. Sumitomo Pharma Business Overview Table 100. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 102. Sumitomo Pharma Recent Development Table 103. Sanofi Company Information Table 104. Sanofi Business Overview Table 105. Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Sanofi Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 107. Sanofi Recent Development Table 108. Neurocrine Company Information Table 109. Neurocrine Business Overview Table 110. Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 112. Neurocrine Recent Development Table 113. Kyowa Kirin Company Information Table 114. Kyowa Kirin Business Overview Table 115. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 117. Kyowa Kirin Recent Development Table 118. Janssen Company Information Table 119. Janssen Business Overview Table 120. Janssen Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Janssen Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 122. Janssen Recent Development Table 123. Bristol-Myers Squibb Company Information Table 124. Bristol-Myers Squibb Business Overview Table 125. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 127. Bristol-Myers Squibb Recent Development Table 128. Acadia Pharmaceuticals Inc. Company Information Table 129. Acadia Pharmaceuticals Inc. Business Overview Table 130. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio Table 132. Acadia Pharmaceuticals Inc. Recent Development Table 133. North America Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026) & (US$ Million) Table 135. North America Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2026) Table 136. North America Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. North America Targeted Drugs for Neurodegenerative Diseases Market Share Forecast by Country (2027-2032) Table 138. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026) & (US$ Million) Table 140. Europe Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2026) Table 141. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Europe Targeted Drugs for Neurodegenerative Diseases Market Share Forecast by Country (2027-2032) Table 143. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026) & (US$ Million) Table 145. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2026) Table 146. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Share Forecast by Country (2027-2032) Table 148. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026) & (US$ Million) Table 150. Latin America Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2026) Table 151. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Latin America Targeted Drugs for Neurodegenerative Diseases Market Share Forecast by Country (2027-2032) Table 153. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026) & (US$ Million) Table 155. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2026) Table 156. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Share Forecast by Country (2027-2032) Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Targeted Drugs for Neurodegenerative Diseases Product Image Figure 3. Global Targeted Drugs for Neurodegenerative Diseases Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Targeted Drugs for Neurodegenerative Diseases Market Size (2021-2032) & (US$ Million) Figure 5. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region: 2025 VS 2032 Figure 6. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region (2021-2032) Figure 7. North America Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Oral Image Figure 13. Global Oral Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Injection Image Figure 15. Global Injection Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Targeted Drugs for Neurodegenerative Diseases Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Type 2025 VS 2032 Figure 18. North America Targeted Drugs for Neurodegenerative Diseases Market Size Share by Type (2021-2032) Figure 19. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Share by Type (2021-2032) Figure 21. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size Share by Type (2021-2032) Figure 23. Parkinson's Disease (PD) Image Figure 24. Global Parkinson's Disease (PD) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Huntington's Disease (HD) Image Figure 26. Global Huntington's Disease (HD) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Multiple Sclerosis (MS) Image Figure 28. Global Multiple Sclerosis (MS) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Tardive Dyskinesia (TD) Image Figure 30. Global Tardive Dyskinesia (TD) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Alzheimer's Disease (AD) Image Figure 32. Global Alzheimer's Disease (AD) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Targeted Drugs for Neurodegenerative Diseases Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Application 2025 VS 2032 Figure 35. North America Targeted Drugs for Neurodegenerative Diseases Market Size Share by Application (2021-2032) Figure 36. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Share by Application (2021-2032) Figure 38. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Targeted Drugs for Neurodegenerative Diseases Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Targeted Drugs for Neurodegenerative Diseases Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2032) Figure 45. Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Targeted Drugs for Neurodegenerative Diseases Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2032) Figure 48. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2032) Figure 51. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Targeted Drugs for Neurodegenerative Diseases Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2032) Figure 54. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Parkinson's Disease (PD)
  • Huntington's Disease (HD)
  • Multiple Sclerosis (MS)
  • Tardive Dyskinesia (TD)
  • Alzheimer's Disease (AD)
Companies covered
  • Eisai Inc.
  • Teva
  • NOVARTIS
  • Green Valley
  • Roche
  • Lundbeck
  • Eli Lilly
  • Biogen
  • UCB
  • Supernus Pharmaceuticals
  • Sumitomo Pharma
  • Sanofi
  • Neurocrine
  • Kyowa Kirin
  • Janssen
  • Bristol-Myers Squibb
  • Acadia Pharmaceuticals Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Targeted Drugs for Neurodegenerative Diseases Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2032)
  5. 1.4.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026)
  6. 1.4.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2027-2032)
  7. 1.5 Key Regions Targeted Drugs for Neurodegenerative Diseases Market Size (2021-2032)
  8. 1.5.1 North America Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (2021-2032)
2 Targeted Drugs for Neurodegenerative Diseases Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Oral
  3. 2.1.2 Injection
  4. 2.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type
  5. 2.2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Targeted Drugs for Neurodegenerative Diseases Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Targeted Drugs for Neurodegenerative Diseases Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Regions
  9. 2.3.1 North America Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Type (2021-2026)
3 Targeted Drugs for Neurodegenerative Diseases Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Parkinson's Disease (PD)
  3. 3.1.2 Huntington's Disease (HD)
  4. 3.1.3 Multiple Sclerosis (MS)
  5. 3.1.4 Tardive Dyskinesia (TD)
  6. 3.1.5 Alzheimer's Disease (AD)
  7. 3.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application
  8. 3.2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size Overview by Application (2021-2032)
  9. 3.2.2 Global Targeted Drugs for Neurodegenerative Diseases Historic Market Size Review by Application (2021-2026)
  10. 3.2.3 Global Targeted Drugs for Neurodegenerative Diseases Market Size Forecasted by Application (2027-2032)
  11. 3.3 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Regions
  12. 3.3.1 North America Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2021-2026)
  13. 3.3.2 Europe Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2021-2026)
  14. 3.3.3 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2021-2026)
  15. 3.3.4 South America Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2021-2026)
  16. 3.3.5 Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Targeted Drugs for Neurodegenerative Diseases Industry Trends
  2. 4.2 Targeted Drugs for Neurodegenerative Diseases Industry Drivers
  3. 4.3 Targeted Drugs for Neurodegenerative Diseases Industry Opportunities and Challenges
  4. 4.4 Targeted Drugs for Neurodegenerative Diseases Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Targeted Drugs for Neurodegenerative Diseases Revenue (2021-2026)
  2. 5.2 Global Targeted Drugs for Neurodegenerative Diseases Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Targeted Drugs for Neurodegenerative Diseases Key Company Headquarters & Area Served
  4. 5.4 Global Targeted Drugs for Neurodegenerative Diseases Company, Product Type & Application
  5. 5.5 Global Targeted Drugs for Neurodegenerative Diseases Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Targeted Drugs for Neurodegenerative Diseases Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Targeted Drugs for Neurodegenerative Diseases Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Targeted Drugs for Neurodegenerative Diseases Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Eisai Inc.
  2. 6.1.1 Eisai Inc. Company Information
  3. 6.1.2 Eisai Inc. Business Overview
  4. 6.1.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  6. 6.1.5 Eisai Inc. Recent Developments
  7. 6.2 Teva
  8. 6.2.1 Teva Company Information
  9. 6.2.2 Teva Business Overview
  10. 6.2.3 Teva Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Teva Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  12. 6.2.5 Teva Recent Developments
  13. 6.3 NOVARTIS
  14. 6.3.1 NOVARTIS Company Information
  15. 6.3.2 NOVARTIS Business Overview
  16. 6.3.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  18. 6.3.5 NOVARTIS Recent Developments
  19. 6.4 Green Valley
  20. 6.4.1 Green Valley Company Information
  21. 6.4.2 Green Valley Business Overview
  22. 6.4.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Green Valley Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  24. 6.4.5 Green Valley Recent Developments
  25. 6.5 Roche
  26. 6.5.1 Roche Company Information
  27. 6.5.2 Roche Business Overview
  28. 6.5.3 Roche Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Roche Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  30. 6.5.5 Roche Recent Developments
  31. 6.6 Lundbeck
  32. 6.6.1 Lundbeck Company Information
  33. 6.6.2 Lundbeck Business Overview
  34. 6.6.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  36. 6.6.5 Lundbeck Recent Developments
  37. 6.7 Eli Lilly
  38. 6.7.1 Eli Lilly Company Information
  39. 6.7.2 Eli Lilly Business Overview
  40. 6.7.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  42. 6.7.5 Eli Lilly Recent Developments
  43. 6.8 Biogen
  44. 6.8.1 Biogen Company Information
  45. 6.8.2 Biogen Business Overview
  46. 6.8.3 Biogen Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Biogen Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  48. 6.8.5 Biogen Recent Developments
  49. 6.9 UCB
  50. 6.9.1 UCB Company Information
  51. 6.9.2 UCB Business Overview
  52. 6.9.3 UCB Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 UCB Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  54. 6.9.5 UCB Recent Developments
  55. 6.10 Supernus Pharmaceuticals
  56. 6.10.1 Supernus Pharmaceuticals Company Information
  57. 6.10.2 Supernus Pharmaceuticals Business Overview
  58. 6.10.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  60. 6.10.5 Supernus Pharmaceuticals Recent Developments
  61. 6.11 Sumitomo Pharma
  62. 6.11.1 Sumitomo Pharma Company Information
  63. 6.11.2 Sumitomo Pharma Business Overview
  64. 6.11.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  66. 6.11.5 Sumitomo Pharma Recent Developments
  67. 6.12 Sanofi
  68. 6.12.1 Sanofi Company Information
  69. 6.12.2 Sanofi Business Overview
  70. 6.12.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Sanofi Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  72. 6.12.5 Sanofi Recent Developments
  73. 6.13 Neurocrine
  74. 6.13.1 Neurocrine Company Information
  75. 6.13.2 Neurocrine Business Overview
  76. 6.13.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  78. 6.13.5 Neurocrine Recent Developments
  79. 6.14 Kyowa Kirin
  80. 6.14.1 Kyowa Kirin Company Information
  81. 6.14.2 Kyowa Kirin Business Overview
  82. 6.14.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  84. 6.14.5 Kyowa Kirin Recent Developments
  85. 6.15 Janssen
  86. 6.15.1 Janssen Company Information
  87. 6.15.2 Janssen Business Overview
  88. 6.15.3 Janssen Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Janssen Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  90. 6.15.5 Janssen Recent Developments
  91. 6.16 Bristol-Myers Squibb
  92. 6.16.1 Bristol-Myers Squibb Company Information
  93. 6.16.2 Bristol-Myers Squibb Business Overview
  94. 6.16.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  96. 6.16.5 Bristol-Myers Squibb Recent Developments
  97. 6.17 Acadia Pharmaceuticals Inc.
  98. 6.17.1 Acadia Pharmaceuticals Inc. Company Information
  99. 6.17.2 Acadia Pharmaceuticals Inc. Business Overview
  100. 6.17.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio
  102. 6.17.5 Acadia Pharmaceuticals Inc. Recent Developments
7 North America
  1. 7.1 North America Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)
  3. 7.3 North America Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)
  3. 8.3 Europe Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)
  3. 10.3 South America Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst